IDEXX Laboratories, Inc. (NASDAQ:IDXX) insider Giovani Twigge sold 2,000 shares of the firm’s stock in a transaction dated Thursday, November 30th. The shares were sold at an average price of $156.07, for a total value of $312,140.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
IDEXX Laboratories, Inc. (IDXX) traded up $4.30 during midday trading on Monday, hitting $159.30. The company had a trading volume of 958,379 shares, compared to its average volume of 702,259. The company has a quick ratio of 0.77, a current ratio of 0.95 and a debt-to-equity ratio of -12.48. The company has a market capitalization of $13,518.90, a PE ratio of 52.19, a PEG ratio of 2.34 and a beta of 0.42. IDEXX Laboratories, Inc. has a 12 month low of $113.71 and a 12 month high of $173.01.
IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, October 31st. The company reported $0.79 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.74 by $0.05. The company had revenue of $492.00 million for the quarter, compared to analysts’ expectations of $492.94 million. IDEXX Laboratories had a negative return on equity of 336.64% and a net margin of 14.55%. IDEXX Laboratories’s quarterly revenue was up 9.7% on a year-over-year basis. During the same period last year, the firm earned $0.62 earnings per share. equities analysts anticipate that IDEXX Laboratories, Inc. will post 3.24 EPS for the current year.
Several analysts recently issued reports on the company. Stifel Nicolaus reissued a “buy” rating and issued a $185.00 target price on shares of IDEXX Laboratories in a research note on Monday, August 21st. Bank of America raised IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $175.00 target price on the stock in a research note on Wednesday, August 23rd. Canaccord Genuity reissued a “buy” rating and issued a $180.00 target price on shares of IDEXX Laboratories in a research note on Tuesday, August 22nd. Finally, Zacks Investment Research cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, October 18th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $173.67.
TRADEMARK VIOLATION NOTICE: “IDEXX Laboratories, Inc. (IDXX) Insider Sells $312,140.00 in Stock” was published by American Banking News and is owned by of American Banking News. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/12/04/idexx-laboratories-inc-idxx-insider-sells-312140-00-in-stock.html.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.